Applied Research on Antimicrobial Resistance

抗菌素耐药性的应用研究

• 批准号: 6909479
• 负责人: John Engemann
• 金额: $ 23.1万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-01 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6909479
• 关键词: Staphylococcus aureus; bacteria infection mechanism; blood disorder; catheterization; clinical research; cost effectiveness; disease /disorder proneness /risk; drug resistance; health care cost /financing; health care facility information system; health care model; health economics; hospital patient care; human data; human old age (65+); mathematical model; methicillin; model design /development; nosocomial infection control; patient safety /medical error; postoperative complications; virulence

The overall purpose of this application is to support research investigating the costs of anti-microbial resistance. Long-term objective: To define the attributable cost of antimicrobial resistance for surgical site infections and bloodstream infections due to Staphylococcus aureus, so that investigators will be able to evaluate the cost effectiveness of proposed methods for the prevention of surgical site infections (SSI) and bloodstream infections (BSI) due to these resistant pathogens. Specific aims: i) To define the attributable impact of methicillin resistance upon economic costs of surgical site infections and bloodstream infections due to S. aureus. 2) To define the incidence and prevalence of surgical site infections and nosocomial bloodstream infections due to methicillin resistant S. aureus (MRSA) in a group of hospitals in the southeastern United States. Methods: The project will utilize 10 study hospitals and an infection control infrastructure that includes 3 physician epidemiologists and over 20 infection control practitioners. Patients with nosocomial bloodstream infections due to S. aureus and SSI are currently identified through prospective surveillance and have been and will continue to be prospectively entered into electronic databases at study hospitals. Additional study data will be obtained from patient charts and hospital databases. For the study of SSI, patients with SSI due to MRSA will be studied as cases and will be compared to patients with SSI due to methicillin susceptible S. aureus (MSSA) and to uninfected control patients who have undergone surgical procedures. For the study of patients with bloodstream infections, patients with BSI due to MRSA will be studied as cases and will be compared to patients with BSI due to MSSA and to uninfected control patients.

本申请的总体目的是支持调查抗微生物耐药性成本的研究。长期目标：确定金黄色葡萄球菌引起的手术部位感染和血流感染的抗菌药物耐药性的可归因成本，以便研究者能够评估预防这些耐药病原体引起的手术部位感染（SSI）和血流感染（BSI）的拟议方法的成本效益。 具体目标：i）确定甲氧西林耐药性对由沙门氏菌引起的手术部位感染和血流感染的经济成本的影响。金黄色。2)明确耐甲氧西林沙门氏菌引起的手术部位感染和院内血流感染的发生率和患病率。金黄色葡萄球菌（MRSA）在美国东南部的一组医院。 研究方法：该项目将利用10家研究医院和一个感染控制基础设施，其中包括3名流行病学医生和20多名感染控制从业人员。由于S.目前通过前瞻性监测确定了金黄色葡萄球菌和SSI，并且已经并将继续前瞻性地输入研究医院的电子数据库。将从患者病历和医院数据库中获取其他研究数据。对于SSI的研究，由于 将作为病例进行研究，并与因甲氧西林敏感性S.金黄色葡萄球菌（MSSA）和未感染的对照患者谁经历了外科手术。对于血流感染患者的研究，将MRSA导致的BSI患者作为病例进行研究，并与MSSA导致的BSI患者和未感染的对照患者进行比较。